A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC

This study is comparing a new targeted treatment — BL-M07D1, an antibody-drug conjugate that delivers chemotherapy directly to cancer cells with HER2 mutations — versus standard pembrolizumab immunotherapy plus platinum chemotherapy, as a first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC) with HER2 mutations. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with advanced or metastatic non-squamous NSCLC - Your tumor has a confirmed HER2 functional (activating) mutation, verified by a central lab - You have not received prior systemic treatment for advanced or metastatic NSCLC - You have good overall health, adequate organ function, and at least one measurable tumor lesion - You have a life expectancy of at least 12 weeks **You may NOT be eligible if...** - Your tumor does not have a HER2 mutation - You have already received systemic treatment for advanced NSCLC - You have significant health conditions that would make treatment unsafe Talk to your doctor to see if this trial is right for you.